Aktienanalyse zu National Research Corp (NRC)NRCNational Research Corp

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. It operates in the Industrials sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.